Literature DB >> 17488381

Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.

Christophe Legendre1, Yves Brault, José M Morales, Rainer Oberbauer, Paolo Altieri, Hany Riad, John Mahony, Maria Messina, Bruce Pussell, Javier G Martínez, Magali Lelong, James T Burke, John F Neylan.   

Abstract

Changes in calculated glomerular filtration rate (GFR) from baseline to five yr were analyzed in relation to risk factors among renal transplant recipients. At three months after transplantation (baseline), 430 eligible patients receiving sirolimus (SRL), cyclosporine (CsA), and steroids (ST) were randomly assigned (1:1) to continue SRL-CsA-ST or have CsA withdrawn and SRL trough levels increased (SRL-ST group). For each risk factor, changes from baseline were compared within each treatment using a t-test and between treatments using ANCOVA. Univariate then multivariate robust linear regression analyses were also performed. In the SRL-ST group, changes from baseline were not significantly different for any risk factor. With the exception of cold ischemia time >24 h, GFR values declined significantly for all risk factors in SRL-CsA-ST patients. For all risk factors, except second transplant or cold ischemia time >24 h, renal function was significantly different between groups. By order of significance in the multivariate analysis, treatment (p < 0.001), donor age (p < 0.001), proteinuria (p < 0.001), and biopsy-confirmed rejection (p = 0.010) were significant predictors of GFR change from baseline. In conclusion, patients with risk factors for reduced renal function benefit from SRL maintenance therapy without CsA vs. those remaining on CsA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488381     DOI: 10.1111/j.1399-0012.2007.00645.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  10 in total

Review 1.  Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.

Authors:  Krishna M Karpe; Girish S Talaulikar; Giles D Walters
Journal:  Cochrane Database Syst Rev       Date:  2017-07-21

Review 2.  Renal transplantation with expanded criteria donors: Which is the optimal immunosuppression?

Authors:  Vassilis Filiopoulos; John N Boletis
Journal:  World J Transplant       Date:  2016-03-24

3.  Minimization vs tailoring: Where do we stand with personalized immunosuppression during renal transplantation in 2015?

Authors:  Lajos Zsom; László Wagner; Tibor Fülöp
Journal:  World J Transplant       Date:  2015-09-24

4.  Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.

Authors:  Kevin Schulte; Clara Vollmer; Vera Klasen; Jan Hinrich Bräsen; Jodok Püchel; Christoph Borzikowsky; Ulrich Kunzendorf; Thorsten Feldkamp
Journal:  J Nephrol       Date:  2017-05-24       Impact factor: 3.902

5.  Recipient efficacy and safety of kidney transplantation from older living donor: consideration for using older kidney as a solution to the shortage of organs.

Authors:  Ji Yeon Song; Kyo Won Lee; Kyunga Kim; Kyeong Deok Kim; Jaehun Yang; Ji Eun Kwon; Okjoo Lee; Jae Berm Park
Journal:  Korean J Transplant       Date:  2021-12-31

6.  Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation.

Authors:  Stephanie R Earnshaw; Christopher N Graham; William D Irish; Reiko Sato; Mark A Schnitzler
Journal:  J Am Soc Nephrol       Date:  2008-06-18       Impact factor: 10.121

7.  Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts.

Authors:  Maarten Naesens; Evelyne Lerut; Hylke de Jonge; Boudewijn Van Damme; Yves Vanrenterghem; Dirk R J Kuypers
Journal:  J Am Soc Nephrol       Date:  2009-09-17       Impact factor: 10.121

8.  Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR).

Authors:  Susanne Brakemeier; Wolfgang Arns; Frank Lehner; Oliver Witzke; Oliver Vonend; Claudia Sommerer; Anja Mühlfeld; Thomas Rath; Robert Schuhmann; Bianca Zukunft; Irena Kroeger; Martina Porstner; Klemens Budde
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

Review 9.  Reviewing 15 years of experience with sirolimus.

Authors:  Helio Tedesco Silva; Claudia Rosso Felipe; Jose Osmar Medina Pestana
Journal:  Transplant Res       Date:  2015-12-22

10.  Conversion from tacrolimus to belatacept improves renal function in kidney transplant patients with chronic vascular lesions in allograft biopsy.

Authors:  María José Pérez-Sáez; Bryant Yu; Audrey Uffing; Naoka Murakami; Thiago J Borges; Jamil Azzi; Sandra El Haji; Steve Gabardi; Leonardo V Riella
Journal:  Clin Kidney J       Date:  2018-12-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.